DMEMEDS shared post via Reuters: Two experimental AstraZeneca drugs show promise in ovarian cancer

(Reuters) - A combination of two drugs developed by AstraZeneca Plc, olaparib and cediranib, was shown in a mid-stage study to nearly double the length of time certain ovarian cancer patients lived without their disease getting worse. [Category: healthNews] http://feeds.reuters.com/~r/reuters/healthNews/~3/UIhUJr3sm_I/story01.htm

Read More